AllDocs -> cancers

14.1. INTRODUCTION AND SUMMARY Table 14.1. Summary of incidence and mortality statistics: bladder cancer INCIDENT CASES DEATHS males females both sexes males females both sexes All cancers (invasive, in situ and uncertain) (ICD-O-2 C67) 1997 cases 345 129 474 115 62 177 % of all cancers 3.3% 1.2% 2.2% 2.9% 1.8% 2.3% Incidence and mortality rates (per 100,000 persons per year) crude rate 19.1 7.0 13.0 6.4 3.4 4.9 World age-standardised rate 14.4 4.7 4.2 1.8 European age-standardised rate 22.4 6.7 7.2 2.8 cumulative risk (0-74) 1.6% 0.6% 0.4% 0.2% mortality/incidence ratio 0.333 0.481 0.373 Time trends (all cancers) 1994 cases 353 175 528 115 71 186 ...

INTRODUCTION Theprocessofcancerprogressionconsistsofmultisteps, which can be rate limiting since a failure or an in- sufficiency at any of the steps aborts the process (1-3). The outcome of the process is dependent on both the intrinsic properties of the tumor cells and the re- sponses of the host. The steps or events required for the formation of tumor invasion and metastasis are the same in all tumors (Fig. 1). The major steps in tumor progression are as follows : 1) After the ini- tial transformation, tumor cells grow at the primary site. 2) Neovascularization must occur when the tumor mass forms 2 mm moreindiameter(4).Several angiogenic factors play key roles to establish neovascularization (5-7). 3) Local invasion of the basement membrane and degradation of the stroma are necessary formigration from the primary site (8-11). Matrix metalloproteinases ...

Preoperative nodal staging of urinary bladder cancer with MRI using ultra small super paramagnetic iron oxide particles Wlliem M.L.L.G. Deserno', Jeile 0. Barentszl, Mukesh G Harisinghani*, M. Taupitz", J, Alfred Witjesz, Peter Mulders2, Jean J.M.C.A. de la Rosettez, Emiel Ruijter3, Christine Hulsbergen-van de Kaa3, R. Weissieder', B. Hamm", Johan G. Blickmanl. Departments of _Radioloav', Urology2 and Pathology3 University Medical Center St. Radboud Nijmegen, Massachusetts General Hospitai,Boston* and Charite, Berlin** The status of the lymph node largely dictates the management of the primary tumor. In order to obtain the pre-operative lymph node status the physician now depends on CT, MRI or PET examinations which only have a low sensitivity. in this study we will prove that we can increase the sensitivity pre-operative by using ...

Phase 1 Clerkship Seminar: Hematuria/ Bladder Cancer Submitted by Dr. Michael Jewett Learning Objectives 1. To learn what constitutes clinically significant hematuria and how to determine the cause. 2. To understand the causes and prevention, how to diagnose and how to treat bladder cancer . Cases 1. A 50 year old woman presents to her family physician for a routine examination. She is otherwise well and asymptomatic urologically. The subsequently reported urinalysis is 2+ for blood • As her family physician, how would you proceed? The repeat is unchanged and microscopic examination reveals 7 rbc/hpf. • As his family physician, how would you proceed? 2. A 65 year old man presents to his family physician with a 1 week history of hematuria. He describes painless red coloration throughout each urination that he assumes is blood. He is otherwise well ...

Abstract. We conducted a randomized controlled trial to compare local recurrence rate after transuretheral resection of superficial bladder cancer treated by either intravesical instillation of an anticancer drug alone (method A) and the intravesical instillation plus oral chemotherapy (doxi- fluridine, 5'-DFUR, an intermediate metabolite of capecitabine) (method B). Results between groups showed no difference in recurrence-free survival curves in 196 patients subjected to primary analysis. However, patients subjected to secondary analysis (method B, over 3 months administration of 5'- DFUR) showed a significantly better prognosis than method A (p=0.0244, Wilcoxon). Regarding correlation between thymidine phosphorylase (TP, an enzyme to convert 5'- DFUR to 5-fluorouracil) level and prognosis, method A patients showed poorer prognosis in higher TP level cases than in lower TP levels. However, there ...

Cancer Program information at www.cedars-sinai.edu/ cancer Call 310-423-2440 or 1-800-CEDARS-1 [1-800-233-2771] for information Cancer -specific Support and Information Page 1 of 6 Cancer Program: Cancer -Specific Support and Information Services The following groups provide information and support related to specific types of cancer . Most services are free of charge. • Bladder Cancer American Foundation for Urologic Disease, Inc. 1128 N. Charles St. Baltimore, MD 21201-2463 Telephone: 410-468-1800 Fax: 410-469-1800 • Breast Cancer Encore Plus Sponsored by the YWCA and provides exercise and support programs Telephone: 202-628-3636 Fax: 202-783-7123 In the Los Angeles area: Greater Los Angeles.213-365-2991 Glendale.818-242-4155 Fullerton .714-871-4488 San Pedro..310-547-0831 Reach to Recovery Program ...

bladder cancer 1146 BLADDER CANCER DIAGNOSTIC AND TREATMENT PATHWAY Gold Standard Timescale Emergency Presentation A&E AP Key Referral to GP Non urgent Emergency Information Flow Patient Flow AP Audited ...

70 16 Cancer of the bladder Summary When compared with other cancer sites, relative survival after diagnosis of bladder cancer is good. During the 1992–1997 period, one-year relative survival after diagnosis with bladder cancer was 86.9% for males and 78.2% for females and five-year relative survival after diagnosis was 70.8% for males and 64.7% for females (Table 16.1). Survival ten years after diagnosis was 65.8% for males and 62.0% for females in 1987–1991, the most recent period for which ten-year relative survival data are available (Figure 16.2; Tables 16.2 and 16.3). Between 1982–1986 and 1992–1997, there were no statistically significant changes in relative survival after diagnosis of bladder cancer for males or females (Figure 16.2; Tables 16.2 and 16.3). As age at diagnosis increased, five-year relative survival decreased. Five-year relative survival was highest for ...

All-Ireland cancer statistics 1994-96 89 Bladder 20. MALIGNANT CANCER OF THE BLADDER (summary) ICD-O.2 C67 ICD-10 C67 ICD-9 188 Key facts • At least 705 cases per year, 1994-96: 210 in females, 495 in males. • Average of 265 deaths per year: 87 in females, 178 in males. • Age-standardised incidence and mortality rates about three times higher in males than females. • 5th most common site for cancer incidence in males, 12th (or higher) in females. • 8th most common cause of cancer deaths in males, 11th in females. • Irish incidence rates above EU average for females, at least, but international comparisons are complicated by lack of consistency in how "malignant" tumours of the bladder are defined. Summary statistics Table 20.1 Incidence 1994-96 On average each year, at least 210 new ...

Expression of b 1 -integrins and N-cadherin in bladder cancer and melanoma cell lines *. Piotr Laidler 1 , Dorota Gil 1 , Anna Pituch-Noworolska 2 , Dorota Cio³czyk 1 , Dorota Ksi¹¿ek 1 , Ma³gorzata Przyby³o 3 and Anna Lityñska 3 1 Institute of Medical Biochemistry, Collegium Medicum, Jagiellonian University, Kraków, 2 Department of Clinical Immunology, Polish-American Children’s Hospital, Collegium Medicum, Jagiellonian University, Kraków, 3 Institute of Zoology, Department of Animal Physiology, Jagiellonian University, Kraków, Poland Received: 29 May, 2000; revised: 20 October, 2000; accepted: 14 November, 2000 Key words: cadherins, integrins, cell lines, cancer , cytofluorimetry Changes in the expression ...

MARCH 2004 European Association of Urology GUIDELINES ON BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC G. Jakse, F. Algaba, S. Fossa, A. Stenzl, C. Sternberg Page 2 TABLE OF CONTENTS PAGE 1 INTRODUCTION 4 2 CLASSIFICATION 4 2.1 TNM staging 4 2.2 Histological grading 4 2.3 References 5 3 RISK FACTORS 5 4 DIAGNOSIS 5 4.1 Symptoms 5 4.2 Physical examination 5 4.3 Cystoscopy and TUR 5 4.4 References 5 5 STAGING 6 5.1 T-staging 6 5.1.1 TUR and bimanual palpation 6 5.1.2 Imaging 6 5.1.2.1 Intravenous pyelography 6 5.1.2.2 Ultrasonography 6 5.1.2.3 Computed tomography 6 5.1.2.4 Magnetic resonance ...

American Urological Association Inc. The Management Bladder Cancer Bladder Cancer of Doctor’s guide for patients on Doctor’s guide for patients on Members: Consultants: Bladder Cancer Guidelines Panel Joseph A. Smith, Jr., MD, Chair Richard F. Labasky, MD, Facilitator James E. Montie, MD Randall G. Rowland, MD Abraham T.K. Cockett, MD John A. Fracchia, MD Members: Consultants: Hanan S. Bell, PhD Patrick M. Florer Curtis Colby Page 2 Copyright © 1999, American Urological Association, Inc. Illustrations prepared by Tim Phelps, C.M.I., Baltimore, MD This guide focuses on non-muscle-invasive bladder cancer . Most of these types of tumors have not spread to the bladder muscle and can be treated without removing any of the ...

Developing a Blaise Instrument for the Spanish Bladder Cancer Study Richard Frey, Westat, U.S. I. Introduction The Spanish Bladder Cancer Study (SBC) is an occupational health epidemiologic study that has involved development and programming of an innovative Blaise computer assisted personal interviewing (CAPI) system for administering, in Spanish, seven core health study sections and sixty-three occupational module questionnaires. There are other study components that involve hospital case ascertainment and control selection in multiple hospital locations throughout Spain, along with a self- administered dietary history questionnaire and blood, urine and toenails specimen collection and shipment. The study is, however, mainly characterized by a large Blaise CAPI system with technically complex programming requirements, an extremely tight design and development schedule, and international study implementation ...

Editorial C a n c e r C o n t r o l July/August 2000, Vol.7, No.4 Cancer Control 307 Transitional cell carcinoma of the bladder is the second most com- mon urologic malignancy after prostate cancer . In the fight against bladder cancer , the clinician is con- fronted with two major clinical sit- uations: first, superficial bladder cancer , which accounts for 80% of bladder cancers at diagnosis, and second, invasive and metastatic bladder cancer . Bladder cancers present in many forms. Most present at diag- nosis as superficial tumors with a tendency to recur but never progress and invade. Others even- tually progress to invasive disease. Relatively few present as invasive disease at diagnosis. When invasive, some will be cured with aggressive local treatment, while ...

Contemporary Management of Superficial Bladder Cancer Julio M.Pow-Sang, MD, and John D.Seigne, MB, BCh Background: Bladder cancer is the second most common urologic malignancy after prostate cancer . Superficial bladder cancer presents as a heterogeneous group of tumors with variable biological potential. A significant percentage of patients diagnosed with superficial cancer will have multiple recurrences, and some will progress to invasive disease. Methods: Patients are stratified into low- or high-risk for recurrence and progression. We review the most recent literature regarding intravesical therapy for superficial bladder cancer , and we summarize indications for the use of intravesical agents as well as their efficacy, toxicity, and cost. Results: Several intravesical agents are available for the treatment of superficial bladder cancer . Patients may be identified ...

Sidi Bou Said,Tunisia, 1999. Courtesy of J. Bryan Murphy, MD, Clearwater, Florida. July/August 2000, Vol.7, No.4 340 Cancer Control Bladder -Sparing Treatment of Invasive Bladder Cancer Inoel Rivera, MD, and Zev Wajsman, MD Background: Radical cystectomy with pelvic lymph node dissection is the standard treatment for patients with invasive bladder cancer . However, many alternative techniques to spare the bladder have been investigated. Methods: We review the experience reported in the literature on bladder -sparing techniques, including transurethral resection, chemotherapy, and radiation for muscle-invasive disease. Results: Most comparative studies indicate that local recurrence and survival outcomes for bladder -sparing approaches are inferior to those from radical cystectomy to control muscle-invasive bladder cancer . Conclusions: Although molecular biologic ...

Molecular Mechanisms and Pathways in Bladder Cancer Development and Progression Ichabod Jung, MD, and Edward Messing, MD Background: The basis for bladder cancer development and progression is complex and involves genetic abnormalities. These abnormalities yield phenotypic changes that allow normal transitional cells to become cancerous and finally acquire the “malignant phenotype.” Methods: The authors review the most common genetic alterations in bladder cancer and the molecular mechanisms and pathways involved in the conversion of normal transitional cell into malignant transitional cancer cells. Results: There are several potential genetic changes of the urothelium that eventually cause bladder cancer initiation and tumor progression. Some of these alterations are also found in other malignancies suggesting that key common pathways exist in the development of cancer ...

Progress in the Management of Metastatic Bladder Cancer Deepika Parimoo, MD, and Derek Raghavan, MD, PhD, FACP, FRACP Background: Inadequate survival results from single agents in the management of advanced bladder cancer have prompted several trials involving multidrug combinations to increase response rates and survival. Methods: Since the development of the MVAC regimen (methotrexate, vinblastine, doxorubicin, and cisplatin) and the CMV regimen (cisplatin, methotrexate, and vinblastine), other regimens have been tested. We evaluate results from regimens that include cisplatin combined with gemcitabine, paclitaxel, or docetaxel, and paclitaxel combined with gemcitabine or carboplatin. Results: Objective results observed with various new combinations are promising. Objective response (OR) rates of 41%, 59%, and 71% are reported with a regimen of gemcitabine plus cisplatin. Paclitaxel ...

Protein limits bladder cancer spread People who have had surgery for bladder cancer can look forward to better survival prospects than those recovering from many other malignancies. Removal of a cancerous blad- der can confer years of life. Some of these patients get shortchanged, however, if their bodies fail to produce enough of a cancer -fighting chemical called p21 protein, researchers report in the July 15 J OURNAL OF THE N ATIONAL C ANCER I NSTITUTE (JNCI). In a study of 242 bladder cancer patients whose bladders had been removed, researchers analyzed tumor tissue taken during surgery. Samples from 86 patients lacked a full comple- ment of p21 protein. Within this group, three-fourths suffered a recurrence of cancer within 5 years of the surgery, and three-fourths of those deficient in p21 died in that time. Of those patients with ...

Home Bladder Cancer Test: A Case Study Medicare patients suffering from bladder cancer cannot gain access to this prescription home-use test because HCFA's payment policies have led to confusion among its local contractors and, in most cases, have resulted in non-payment for the test. Summary Confusion and uncertainty over the Health Care Financing Administration’s (HCFA) decision to cut payment by roughly 70 percent for this test has led Medicare's local contractors to stop payment for the test altogether, thus virtually stopping all access for Medicare patients. The change in reimbursement results from HCFA's judgement that it will no longer permit providers to use the "immunoassay for tumor antigen" code when they bill for the device—even though FDA approved the device as an immunoassay for tumor antigens (proteins created by cancer cells). HCFA insists that providers must ...

19 TABLE 9. BLADDER CANCER INCIDENCE BY COUNTY, RACE AND GENDER, NEW JERSEY - 1986-1996 COMBINED 1 COUNTY MALE FEMALE WHITE BLACK WHITE BLACK Number Rate Number Rate Number Rate Number Rate 2 2 2 2 Atlantic 468 40.0 28 15.1 159 9.5 23 7.4 Bergen 2020 39.0 31 18.2 761 10.7 15 5.3 Burlington 683 39.8 35 20.3 220 9.5 15 7.4 Camden 866 38.3 48 16.0 350 10.7 29 6.9 Cape May 286 37.5 9 36.8 109 10.6 6 16.4 Cumberland 229 33.2 8 10.4 88 9.1 6 5.3 Essex 1028 35.3 162 14.8 413 9.6 98 5.5 Gloucester ...

16 TABLE 6. BLADDER CANCER INCIDENCE BY COUNTY, WHITE MALES, NEW JERSEY - 1986-1996 1 COUNTY 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 (Prelim.) No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate Atlantic 31 30.7 35 35.0 42 40.5 46 44.7 45 44.1 42 39.2 56 50.4 45 39.9 37 32.3 44 40.3 45 40.7 Bergen 163 35.9 198 43.5 192 41.2 196 42.7 182 38.8 188 40.6 192 40.7 204 42.4 172 35.8 155 32.0 178 36.6 Burlington 54 37.7 43 29.4 67 45.4 53 34.8 75 46.9 67 43.0 69 43.3 63 39.8 56 34.9 73 44.5 63 37.4 Camden 63 31.7 79 40.0 82 41.1 79 37.9 86 41.7 70 33.8 85 42.1 79 37.6 78 37.8 82 ...

18 BLADDER CANCER INCIDENCE BY COUNTY, BLACKS BY GENDER, NEW JERSEY - 1986-1990 AND 1991-1996 1 COUNTY 1986-1990 1991-1996 MALE FEMALE MALE FEMALE Number Rate Number Rate Number Rate Number Rate 2 2 2 2 Atlantic 13 17.1 11 8.5 15 13.7 12 6.6 Bergen 19 25.9 8 6.8 12 12.5 7 4.2 Burlington 18 27.9 5 6.2 17 15.3 10 8.2 Camden 13 11.2 14 8.2 35 19.4 15 5.9 Cape May 5 46.9 5 35.2 --- --- --- --- Cumberland 6 18.7 --- --- --- --- --- --- Essex 64 13.2 53 6.8 98 16.0 45 4.6 Gloucester 7 18.3 ...

17 BLADDER CANCER INCIDENCE BY COUNTY , WHITE FEMALES, NEW JERSEY - 1986-1996 1 COUNTY 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 (Prelim.) No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate Atlantic 13 10.1 17 11.2 11 7.2 16 10.8 18 10.7 13 7.8 10 6.8 14 9.5 15 9.9 12 8.4 20 12.2 Bergen 72 11.4 73 11.4 62 9.9 73 11.9 67 10.3 71 10.4 82 13.1 73 10.9 60 8.8 61 9.1 67 10.7 Burlington 23 11.5 9 4.3 16 7.4 20 9.4 24 11.0 25 12.8 19 8.7 23 11.1 21 10.1 21 9.8 19 9.1 Camden 32 11.1 30 10.5 29 9.2 30 9.9 25 ...

Biochem. J. (1997) 321 , 889–895 (Printed in Great Britain) 889 Biochemical analysis of a bladder - cancer -associated mucin: structural features and epitope characterization Alain BERGERON, He!le'ne L A RUE and Yves FRADET* Laboratoire d’Uro-Oncologie Expe!rimentale, Centre de recherche de l’Ho#tel-Dieu de Que!bec, 11 co#te du Palais, Que!bec, Canada G1R 2J6 Three monoclonal antibodies (mAbs), M344, M300 and M75, were shown to define a unique tumour-associated antigen (TAA) of superficial bladder tumours. The antigenic determinants are expressed on a very-high-molecular-mass component and, in about 50% of the positive samples, one determinant is also detected on a 62 kDa molecular species, observed only under reducing conditions. The objectives of the present study were to characterize further this TAA by analysing (1) the biochemical nature of the epitopes recognized ...

Bladder Cancer Beth Ruyak/Host “For people suffering from bladder cancer , the standard approach has been to remove the bladder , which meant the patient had to wear a bag to collect urine. This method served many people well but seriously affected their quality of life. Now, new and less intrusive treatment options without the bag have become available.” RICHARD MANNING SPENDS MOST OF HIS DAYS IN HIS GARAGE WOODWORKING. IT’S A HOBBY THAT HAS BECOME THIS RETIRED PRINTER’S SECOND CAREER. BUT THERE WAS A TIME WHEN A SECOND CAREER WAS NOT FORESEEABLE IN RICHARD’S FUTURE. Richard Manning/ Bladder Cancer Survivor “I was passing stones. I had lower back pains and pains in my hip area, and they said I had rheumatism.” “THEY” WERE THE MANY DOCTORS RICHARD VISITED TRYING TO DISCOVER WHAT WAS WRONG WITH HIM. FINALLY, ONE DOCTOR TOOK AN X-RAY AND FOUND OUT. Manning “And it was a shock ...